ClinicalTrials.Veeva

Menu

Morbidity in Open Versus Minimally Invasive Esophagectomy (MIOMIE)

A

Austrian Society Of Surgical Oncology

Status

Completed

Conditions

Esophageal Cancer

Treatments

Procedure: open esophagectomy
Procedure: minimally invasive esophagectomy

Study type

Interventional

Funder types

Other

Identifiers

NCT03035071
AUT-MIOMIE-RCT

Details and patient eligibility

About

The MIOMIE trial is a prospective randomized controlled study comparing open and laparoscopic gastric tube formation in Ivor Lewis esophagectomy. Aim of this trial was to compare the minimally invasive approach with the standard open procedure regarding morbidity and mortality.

Full description

Esophageal resection is still associated with considerable morbidity and mortality. Standardized preoperative efforts could increase the outcome of these patients. While early reports of medical pioneers focused particularly on safety and feasibility, more recent studies showed that implementation of minimally invasive esophagectomy (MIE) was widely accepted. Since first reports of MIE, different techniques and adjustments have been discussed. A recent publication of a large prospective trial in Phase II showed the safety of a total minimally invasive approach (video assisted thoracoscopic surgery (VATS) and laparoscopy). Surgical technique however is still a subject of debate and the level of evidence remains still low. Proving feasibility does not warrant a paradigm shift, as experience is an important factor for safety and patient benefit.

The aim of this study was to evaluate morbidity and mortality of open esophagectomy (OE) versus hybrid-MIE in a randomized controlled setting.

Prior to surgery patients will be randomized either the minimally invasive surgery group (laparoscopic gastric tube formation and thoracotomy) or the the open surgery group (open gastric tube formation with an open laparotomy approach). Randomizing tool is the "randomizer" of the medical university of vienna. (link is attached below)

Enrollment

26 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • adenocarcinoma of the esophagus and the esophagogastric junction in (Siewert) type I and II position
  • esophageal squamous cell cancer
  • patients, who require esophageal resection due to above mentioned diagnosis
  • patients, who gave their informed consent

Exclusion criteria

  • individuals who did not meet the inclusion criteria were excluded from the study.
  • patients with tumor localization in the upper third of the esophagus and requiring cervical resection were excluded.
  • patients, presenting other than AC or ESCC or showed contraindication for laparoscopy (history of large abdominal surgery or signs of hostile abdomen)
  • patients with a history or presence of any other malignancy, except carcinoma in situ or basalioma

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

26 participants in 2 patient groups

minimally invasive esophagectomy
Experimental group
Description:
minimally invasive (laparoscopic) gastric mobilisation and gastric tube formation.
Treatment:
Procedure: minimally invasive esophagectomy
open esophagectomy
Active Comparator group
Description:
open gastric mobilization and gastric tube formation
Treatment:
Procedure: open esophagectomy

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems